Efficacy of nirsevimab for the prevention of RSV disease in infants: A systematic review, meta-analysis of randomized controlled trials, and global perspectives on recommendations and unmet needs

Respiratory syncytial virus (RSV) is a major cause of infant hospitalizations, with limited prophylactic options historically available. Nirsevimab, a long-acting monoclonal antibody, has emerged as a promising agent for preventing RSV. To evaluate the efficacy and safety of nirsevimab through a sys...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Pediatrics and neonatology
Hlavní autori: Lien, Hsin-Chweng, Lien, Chi-Hone, Liu, Tzu-Yu, Weng, Shun-Long, Tai, Yu-Lin, Huang, Ya-Ning, Chi, Hsin, Chiu, Nan-Chang, Yeung, Chun-Yan, Lin, Chien-Yu
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: Singapore Elsevier B.V 13.11.2025
Predmet:
Beyfortus
Internal Medicine
Monoclonal antibody
Nirsevimab
Passive immunity
Pediatrics
Respiratory syncytial virus
RSV
Seasonality
Traveller
Beyfortus
Respiratory syncytial virus
RSV
Seasonality
Passive immunity
Monoclonal antibody
Traveller
Nirsevimab
passive immunity
monoclonal antibody
respiratory syncytial virus
traveller
seasonality
nirsevimab
ISSN:1875-9572, 2212-1692, 2212-1692
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Respiratory syncytial virus (RSV) is a major cause of infant hospitalizations, with limited prophylactic options historically available. Nirsevimab, a long-acting monoclonal antibody, has emerged as a promising agent for preventing RSV. To evaluate the efficacy and safety of nirsevimab through a systematic review and meta-analysis of randomized controlled trials (RCTs) and investigate current global recommendations. Databases, including PubMed, Embase, and Cochrane CENTRAL, were searched from inception to January 31, 2025. Eligible RCTs assessing nirsevimab efficacy in RSV prevention were included. Outcomes encompassed RSV-related hospitalization, severe infection, and adverse events. Meta-analysis employed random-effects models. Six RCTs (n = 12,086) were included. Nirsevimab significantly reduced RSV-related hospitalization (odds ratio [OR], 0.19; 95 % confidence interval [CI], 0.13–0.30) and severe RSV infection (OR, 0.23; 95 % CI, 0.12–0.44), with no increase in adverse events. Country-specific recommendations varied, ranging from seasonal to year-round strategies. Nirsevimab exhibits excellent efficacy and safety in RSV prevention. Although most countries align administration with RSV seasonality, Taiwan distinctively endorses year-round prophylaxis. Customized immunization policies considering local epidemiology and seasonality may optimize protection and inform global RSV prevention strategies.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1875-9572
2212-1692
2212-1692
DOI:10.1016/j.pedneo.2025.10.004